« Return to News | Clinical Intelligence

FDA lifts hold on Insmed’s Arikace

Friday, January 20, 2012 02:49 PM

The FDA has lifted the clinical hold previously placed on Insmed’s Arikace (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease. However, Insmed is still engaged in discussions with the FDA regarding the clinical hold placed on Arikace in cystic fibrosis (CF) patients with Pseudomonas lung infections.

The clinical holds placed on the Arikace programs in NTM and CF were based on an initial review by the FDA of the results reported by Insmed of a long-term rat inhalation carcinogenicity study of Arikace. The FDA requested Insmed conduct a phase II clinical trial of Arikace in adult patients with NTM to provide proof-of-concept efficacy and safety data before proceeding with a phase III clinical trial.

As a result of the lifted hold, Insmed will move ahead with the nine-month dog inhalation toxicity study of Arikace requested by the FDA to determine if the findings of the rat inhalation carcinogenicity study are observed in a non-rodent model.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.